ArticleMolecular psychiatry2023
Chemogenetic manipulation of CX3CR1
Article in Molecular psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 11 citations in OpenAlex.
- An unrecognized mechanism of neuroprotection by microglial TIA1-mediated stress granules to prevent neuroinflammation and demyelination in experimental autoimmune encephalomyelitis mice through sequestering ApoE mRNA.Journal of neuroinflammation · 2026Article
- Aging effects on emotionality, cognition and brain mononuclear cells in Sprague-Dawley rats of both sexes.npj aging · 2026Article
- Microglia contribute to bipolar depression through Serinc2-dependent phospholipid synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Chemogenetic activation of microglial Gi signaling decreases microglial surveillance and impairs neuronal synchronization.Science advances · 2025Article
- Gene therapy for chronic pain management.Cell reports. Medicine · 2024Review
- CCR2Cell reports · 2024Article
- Tuning neural circuits and behaviors by microglia in the adult brain.Trends in neurosciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Chemogenetic approaches using Designer Receptors Exclusively Activated by Designer Drugs (DREADD, a family of engineered GPCRs) were recently employed in microglia. Here, we used Cx3cr1
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.